Form 4: Merit Medical Systems CFO Raul Parra Jr. Reports Stock Transactions
SEC Form 4 Filing
CFO Raul Parra Jr. reports acquisition and disposal of Merit Medical Systems stock, including grants of restricted stock units and performance stock units, as well as shares surrendered for tax obligations.
Summary
- Raul Parra Jr., CFO and Treasurer of Merit Medical Systems, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On March 4, 2024, Parra acquired 7,319 shares of common stock through a grant of restricted stock units (RSUs) and 7,110 shares through performance stock units.
- Also on March 4, 2024, Parra disposed of 2,630 shares to satisfy tax withholding obligations related to the issuance of performance stock units at a price of $76.51.
- Following these transactions, Parra directly owns 18,487 shares of common stock and indirectly owns 2,770 shares through a 401(k) plan.
- Parra also holds non-qualified stock options to purchase a total of 82,549 shares of common stock at various exercise prices and expiration dates.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The acquisitions of shares through RSUs and performance stock units are a positive sign, while the disposal of shares for tax obligations is a routine event.
Positives
- The acquisition of shares through RSUs and performance stock units indicates confidence in the company's future performance.
- The vesting schedules of the RSUs and stock options incentivize long-term commitment from the CFO.
Negatives
- The disposal of shares to cover tax obligations, while routine, slightly reduces Parra's direct holdings.
Risks
- Future fluctuations in the stock price could impact the value of Parra's holdings and stock options.
- Changes in company performance could affect the vesting of RSUs and performance stock units.
Future Outlook
The vesting schedules of RSUs and stock options suggest a continued commitment from the CFO to the company's long-term success.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates the CFO's ongoing investment in the company.
Comparison to Industry Standards
- Stock option and RSU grants are a common form of executive compensation in the medical device industry, aligning management's interests with those of shareholders.
- Companies like Medtronic, Boston Scientific, and Abbott also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- The transactions may have a minor positive impact on shareholder confidence due to the CFO's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 03/02/2019 | First date that non-qualified stock options become exercisable. |
| 03/01/2020 | First date that non-qualified stock options become exercisable. |
| 02/26/2021 | First date that non-qualified stock options become exercisable. |
| 03/19/2021 | Date of grant for performance stock units. |
| 03/19/2022 | First date that non-qualified stock options become exercisable. |
| 02/28/2023 | First date that non-qualified stock options become exercisable. |
| 02/28/2024 | First date that non-qualified stock options become exercisable. |
| 03/04/2024 | Date of stock transactions (acquisition and disposal). |
| 03/06/2024 | Date of Form 4 signature. |
| 03/02/2025 | Expiration date of non-qualified stock options. |
| 03/01/2026 | Expiration date of non-qualified stock options. |
| 02/26/2027 | Expiration date of non-qualified stock options. |
| 03/19/2028 | Expiration date of non-qualified stock options. |
| 02/28/2029 | Expiration date of non-qualified stock options. |
| 02/28/2030 | Expiration date of non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.